/Investor DB

Michigan Capital Network — 2026 Investments

5 investments dated 2026 · listed companies and verified rows first · show all

Akadeum Life Sciencesakadeum.comin𝕏Jun 2026

Akadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products.

Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesAnn Arbor, US

Kalyan Handique(Executive Officer, Director)John Younger(Executive Officer, Director)inJames Militello(Executive Officer)

BoardJeffrey S. Williams(Director)Dan Kidle(Director)in

Board seatJenni LiPaul D'Amato· per SEC Form D

Co-investorsArboretum VenturesBeringeaBerkeley CatalystBlueStone Venture PartnersCANTILEVER INVESTORSeLab Ventures+7 more

Modalmotorsmodalmotors.comJan 2026

Farmington Hills, US

Kent Helfrich(Executive Officer)Ebru Van Steenburg(Executive Officer)Michael Van Steenburg(Executive Officer, Director)James Burton(Executive Officer)inFatih Arslan(Executive Officer)

Board seatPaul D'Amato· per SEC Form D

Fluxworksfluxworks.coin𝕏Jan 2026 · $5M

FluxWorks develops magnetic gearing technology for motion systems, replacing traditional mechanical gears with contactless magnetic solutions.

Advanced ManufacturingDeep TechHardwareRoboticsTexas, US

Bryton Praslicka(Chief Executive Officer)

BoardBradley Harrison(Director)in

Co-investorsACADEMY INVESTORAggie Angel NetworkAIN VenturesHouston Angel NetworkScout VenturesScout Ventures

Provenairprovenair.cominAug 2026

ProvenAir provides technology services for trace quality management and documentation automation within the commercial aerospace industry, helping operators and suppliers digitize and verify material provenance records.

AI & Machine LearningEnterprise SoftwareSaaSChicago, US

Chris Kubinski(CEO)inNate Brochmann(Executive Officer)inStephanie Boccarossa(Director)James Boccarossa(Executive Officer, Director)

BoardSapna Patel(Director)Abid Ali(Director)

Co-investorsMairs & Power VCVictorum

TACIT THERAPEUTICStacittx.cominMar 2026

Tacit Therapeutics develops RNA-based gene therapy approaches by redirecting cellular splicing processes to repair mutated genes.

BiotechDeep TechHealthtechSan Francisco, US

Co-investorsCivilization Ventures Management, LlcEisai Innovation, Inc.KdT VenturesLaurier Startup FundMitsui Global Investment

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.